Date: 2014-11-18
Type of information: Opening of new premises
Compound: active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo
Company: Xellia Pharmaceuticals (Denmark)
Therapeutic area: Infectious diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On November 18, 2014, Xellia Pharmaceuticals announced the opening of a new active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo, Norway. Xellia specializes in the manufacture of quality, fermented and difficult-to-manufacture APIs. The new 1,900m2 state-of-the-art facility replaces the R&D center at the former manufacturing site in Oslo. Xellia’s 50 specialist API researchers are focusing on developing new APIs and on the identification of improvements in microbial strain development as well as fermentation and purification processes to increase the yield and efficiencies in the upstream and downstream manufacturing process. This work supports the development of new treatments, and the manufacture and continuity of supply of existing treatments for serious and life threatening diseases to better serve Xellia’s over 500 pharmaceutical customers in more than 70 countries.
- The research team is also working in partnership with scientists at SINTEF Materials and Chemistry (Trondheim, Norway) and the Statens Serum Institute (Copenhagen, Denmark). The scientists are collaborating in research into resistant bacteria with the goal to improve and revive the use of existing important last-line anti-infective treatments. Developing safer antibiotics will extend their utility making them more suitable for intended therapeutic administration. In addition, Xellia is working with these partners to discover new lead compunds that will target multi-drug resistant Gram-negative bacteria which cause severe and hard to treat diseases. These programs are supported by the Research Council of Norway (NFR). The new API R&D Center of Excellence is part of the latest phase of Xellia’s on-going expansion plans which included the investment in the Company’s Finished Dosage Form R&D Center of Excellence in Zagreb, Croatia in May and the acquisition of Fresenius Kabi’s US manufacturing plant in Raleigh, NC, USA in July.
- Xellia is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway. Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.
Financial terms:
Latest news:
Is general: Yes
